5-Amino-1MQ 'Dosing': What Vendors Claim and Evidence Supports
No validated human dose of 5-amino-1MQ exists. Rodent studies inform mechanism, not milligrams. Here is what the evidence actually supports.
14 source-based articles maintained by the HealthRX.com Editorial Team.

Showing 14 of 14 clinical reviews.
No validated human dose of 5-amino-1MQ exists. Rodent studies inform mechanism, not milligrams. Here is what the evidence actually supports.
5-amino-1MQ is studied in preclinical models for NNMT-linked muscle metabolism; no cited human sarcopenia trial has tested the compound itself as of Sept 2026.
5-amino-1MQ weight loss evidence comes entirely from mouse studies. No human trials exist. Here is what the rodent data actually showed.
No human safety data exist for 5-amino-1MQ. Here is what animal and enzymology research suggests about risk, and what remains unverified.
5-amino-1MQ has no human trials; berberine has human RCT history. Compare evidence tiers, mechanisms, and what each gap means for decisions.
5-amino-1MQ has no human weight-loss trials; semaglutide and tirzepatide have large randomized trials and FDA approval. Here is why that gap matters.
5-Amino-1MQ inhibits NNMT, an enzyme linking methylation and NAD+ salvage; the mechanism is well studied preclinically, human metabolic effects are not.
5-amino-1MQ has no FDA-approved use and is not on the 503A bulks list. Here is what its current regulatory status actually means for buyers.
5-amino-1MQ has strong rodent NNMT-inhibition data and no human trials. This editorial argues the mouse-to-human translation gap is being sold as settled science.
5-amino-1MQ blocks the NNMT enzyme in rodent studies, altering NAD+ and methylation balance in fat cells; human mechanism data remain unpublished as of 2026.
5-amino-1MQ is sold as an unregulated research chemical with no FDA-approved use. Here is how to read purity claims and vendor red flags.
5-amino-1MQ pricing varies by purity testing, batch source, and seller type, not by proven efficacy, since no dosing or quality standard is FDA-established.
5-amino-1MQ is an experimental small-molecule NNMT inhibitor, not a peptide or approved drug. Evidence is mostly preclinical.
5-amino-1MQ is capsule-dosed because it is a small molecule, not a peptide, but oral rat pharmacokinetic data does not establish human bioavailability or efficacy.